{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T03:36:37Z","timestamp":1792985797166,"version":"4.5.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,1,29]],"date-time":"2025-01-29T00:00:00Z","timestamp":1738108800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,1,29]],"date-time":"2025-01-29T00:00:00Z","timestamp":1738108800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer"],"published-print":{"date-parts":[[2025,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Antibody\u2013drug conjugates (ADCs) are an emerging class of anticancer therapy that combines the specificity and long circulation half-life of monoclonal antibodies with the cytotoxic potency of the payload connected through a chemical linker. The optimal management of toxicities is crucial for improving quality of life in patients undergoing ADCs and for avoiding improper dose reductions or discontinuations. This article focuses on the characteristics and management of nausea and vomiting (NV) induced by three ADCs: trastuzumab deruxtecan (T-DXd), sacituzumab govitecan (SG), and datopotamab deruxtecan (Dato-DXd). We summarize the proposed mechanism of NV, clinical study data on NV, and recommendations from clinical guidelines. We also discuss three prospective studies evaluating prophylactic antiemetic therapy in patients receiving T-DXd, along with future perspectives.<\/jats:p>","DOI":"10.1007\/s12282-025-01670-1","type":"journal-article","created":{"date-parts":[[2025,1,29]],"date-time":"2025-01-29T12:10:00Z","timestamp":1738152600000},"page":"278-285","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Management of nausea and vomiting induced by antibody\u2013drug conjugates"],"prefix":"10.1007","volume":"32","author":[{"given":"Jawhara","family":"Farhat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8396-9121","authenticated-orcid":false,"given":"Hitomi","family":"Sakai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junji","family":"Tsurutani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,29]]},"reference":[{"key":"1670_CR1","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1038\/s41571-023-00783-w","volume":"20","author":"P Tarantino","year":"2023","unstructured":"Tarantino P, Ricciuti B, Pradhan SM, Tolaney SM. Optimizing the safety of antibody-drug conjugates for patients with solid tumours. Nat Rev Clin Oncol. 2023;20:558\u201376.","journal-title":"Nat Rev Clin Oncol"},{"key":"1670_CR2","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1056\/NEJMoa2115022","volume":"386","author":"J Cort\u00e9s","year":"2022","unstructured":"Cort\u00e9s J, Kim S-B, Chung W-P, Im S-A, Park YH, Hegg R, et al. Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer. N Engl J Med. 2022;386:1143\u201354.","journal-title":"N Engl J Med"},{"key":"1670_CR3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2203690","author":"S Modi","year":"2022","unstructured":"Modi S, Jacot W, Yamashita T, Sohn J, Vidal M, Tokunaga E, et al. Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. N Engl J Med. 2022. https:\/\/doi.org\/10.1056\/NEJMoa2203690.","journal-title":"N Engl J Med"},{"key":"1670_CR4","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1056\/NEJMoa2028485","volume":"384","author":"A Bardia","year":"2021","unstructured":"Bardia A, Hurvitz SA, Tolaney SM, Loirat D, Punie K, Oliveira M, et al. Sacituzumab govitecan in metastatic triple-negative breast cancer. N Engl J Med. 2021;384:1529\u201341.","journal-title":"N Engl J Med"},{"key":"1670_CR5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.24.00920","author":"A Bardia","year":"2024","unstructured":"Bardia A, Jhaveri K, Im SA, Pernas S, De Laurentiis M, Wang S, et al. Datopotamab deruxtecan versus chemotherapy in previously treated inoperable\/metastatic hormone receptor-positive human epidermal growth factor receptor 2-negative breast cancer: primary results from TROPION-Breast01. J Clin Oncol. 2024. https:\/\/doi.org\/10.1200\/JCO.24.00920.","journal-title":"J Clin Oncol"},{"key":"1670_CR6","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.critrevonc.2015.12.001","volume":"99","author":"S Sommariva","year":"2016","unstructured":"Sommariva S, Pongiglione B, Tarricone R. Impact of chemotherapy-induced nausea and vomiting on health-related quality of life and resource utilization: a systematic review. Crit Rev Oncol Hematol. 2016;99:13\u201336.","journal-title":"Crit Rev Oncol Hematol"},{"key":"1670_CR7","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1056\/NEJMra1515442","volume":"374","author":"RM Navari","year":"2016","unstructured":"Navari RM, Aapro M. Antiemetic prophylaxis for chemotherapy-induced nausea and vomiting. N Engl J Med. 2016;374:1356\u201367.","journal-title":"N Engl J Med"},{"key":"1670_CR8","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s00520-018-4131-3","volume":"26","author":"M Aapro","year":"2018","unstructured":"Aapro M. CINV: still troubling patients after all these years. Support Care Cancer. 2018;26:5\u20139.","journal-title":"Support Care Cancer"},{"key":"1670_CR9","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s00520-019-05012-8","volume":"28","author":"RJ Wickham","year":"2020","unstructured":"Wickham RJ. Revisiting the physiology of nausea and vomiting-challenging the paradigm. Support Care Cancer. 2020;28:13\u201321.","journal-title":"Support Care Cancer"},{"key":"1670_CR10","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1097\/PPO.0b013e31816a0f07","volume":"14","author":"L Lohr","year":"2008","unstructured":"Lohr L. Chemotherapy-induced nausea and vomiting. Cancer J. 2008;14:85\u201393.","journal-title":"Cancer J"},{"key":"1670_CR11","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.tvjl.2014.10.007","volume":"203","author":"H Kenward","year":"2015","unstructured":"Kenward H, Pelligand L, Savary-Bataille K, Elliott J. Nausea: current knowledge of mechanisms, measurement and clinical impact. Vet J. 2015;203:36\u201343.","journal-title":"Vet J"},{"key":"1670_CR12","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.1016\/S1470-2045(17)30604-6","volume":"18","author":"T Doi","year":"2017","unstructured":"Doi T, Shitara K, Naito Y, Shimomura A, Fujiwara Y, Yonemori K, et al. Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody-drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study. Lancet Oncol. 2017;18:1512\u201322.","journal-title":"Lancet Oncol"},{"key":"1670_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)02420-5","author":"N Harbeck","year":"2024","unstructured":"Harbeck N, Ciruelos E, Jerusalem G, M\u00fcller V, Niikura N, Viale G, et al. Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b\/4 trial. Nat Med. 2024. https:\/\/doi.org\/10.1016\/S0140-6736(22)02420-5.","journal-title":"Nat Med"},{"key":"1670_CR14","unstructured":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) Antiemesis, version 2 (2024)"},{"key":"1670_CR15","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s00520-023-08222-3","volume":"32","author":"F Scott\u00e9","year":"2023","unstructured":"Scott\u00e9 F, Schwartzberg L, Lihara H, Aapro M, Gralla R, Hesketh PJ, et al. 2023 updated MASCC\/ESMO Consensus recommendations: Prevention of nausea and vomiting following moderately emetic risk antineoplastic agents. Support Care Cancer. 2023;32:45.","journal-title":"Support Care Cancer"},{"key":"1670_CR16","doi-asserted-by":"publisher","first-page":"2782","DOI":"10.1200\/JCO.20.01296","volume":"38","author":"PJ Hesketh","year":"2020","unstructured":"Hesketh PJ, Kris MG, Basch E, Bohlke K, Barbour SY, Clark-Snow RA, et al. Antiemetics: ASCO guideline update. J Clin Oncol. 2020;38:2782\u201397.","journal-title":"J Clin Oncol"},{"key":"1670_CR17","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1007\/s10147-024-02535-x","volume":"29","author":"H Iihara","year":"2024","unstructured":"Iihara H, Abe M, Wada M, Iino K, Akechi T, Imamura CK, et al. 2023 Japan Society of clinical oncology clinical practice guidelines update for antiemesis. Int J Clin Oncol. 2024;29:873\u201388.","journal-title":"Int J Clin Oncol"},{"key":"1670_CR18","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1111\/cas.12146","volume":"104","author":"I Sekine","year":"2013","unstructured":"Sekine I, Segawa Y, Kubota K, Saeki T. Risk factors of chemotherapy-induced nausea and vomiting: index for personalized antiemetic prophylaxis. Cancer Sci. 2013;104:711\u20137.","journal-title":"Cancer Sci"},{"key":"1670_CR19","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1007\/s00520-018-4403-y","volume":"27","author":"D Tsuji","year":"2019","unstructured":"Tsuji D, Suzuki K, Kawasaki Y, Goto K, Matsui R, Seki N, et al. Risk factors associated with chemotherapy-induced nausea and vomiting in the triplet antiemetic regimen including palonosetron or granisetron for cisplatin-based chemotherapy: analysis of a randomized, double-blind controlled trial. Support Care Cancer. 2019;27:1139\u201347.","journal-title":"Support Care Cancer"},{"key":"1670_CR20","doi-asserted-by":"publisher","first-page":"5097","DOI":"10.1158\/1078-0432.CCR-15-2822","volume":"22","author":"Y Ogitani","year":"2016","unstructured":"Ogitani Y, Aida T, Hagihara K, Yamaguchi J, Ishii C, Harada N, et al. DS-8201a, a novel HER2-targeting ADC with a novel DNA Topoisomerase I inhibitor, demonstrates a promising antitumor efficacy with differentiation from T-DM1. Clin Cancer Res. 2016;22:5097\u2013108.","journal-title":"Clin Cancer Res"},{"key":"1670_CR21","doi-asserted-by":"publisher","first-page":"12118","DOI":"10.1200\/JCO.2024.42.16_suppl.12118","volume":"42","author":"YH Park","year":"2024","unstructured":"Park YH, Cort\u00e9s J, Modi S, Hurvitz SA, Bianchini G, Iwata H, et al. Pooled analysis on characteristics of nausea and vomiting in patients receiving trastuzumab deruxtecan (T-DXd) in clinical studies. J Clin Oncol. 2024;42:12118.","journal-title":"J Clin Oncol"},{"key":"1670_CR22","doi-asserted-by":"publisher","first-page":"S632","DOI":"10.1016\/j.annonc.2022.07.256","volume":"33","author":"NT Ueno","year":"2022","unstructured":"Ueno NT, Jacot W, Yamashita T, Sohn J, Tokunaga E, Prat A, et al. 217O Patient-reported outcomes (PROs) from DESTINY-Breast04, a randomized phase III study of trastuzumab deruxtecan (T-DXd) vs treatment of physician\u2019s choice (TPC) in patients (pts) with HER2-low metastatic breast cancer (MBC). Ann Oncol. 2022;33:S632\u20133.","journal-title":"Ann Oncol"},{"key":"1670_CR23","doi-asserted-by":"publisher","first-page":"S1214","DOI":"10.1016\/j.annonc.2024.08.2260","volume":"35","author":"X Hu","year":"2024","unstructured":"Hu X, Curigliano G, Yonemori K, Bardia A, Barrios CHE, Sohn J, et al. LBA22 Effects of trastuzumab deruxtecan (T-DXd) vs choice of chemotherapy (TPC) on patient-reported outcomes (PROs) in hormone receptor-positive, HER2-low or HER2-ultralow metastatic breast cancer (mBC): results from DESTINY-Breast06. Ann Oncol. 2024;35:S1214\u20135.","journal-title":"Ann Oncol"},{"key":"1670_CR24","doi-asserted-by":"publisher","first-page":"S1639","DOI":"10.1016\/j.annonc.2023.10.540","volume":"34","author":"A Ooki","year":"2023","unstructured":"Ooki A, Aoyama T, Oba K, Nishikawa K, Kawabata R, Honda M, et al. 454P a multicenter randomized open-label phase II study investigating optimal antiemetic therapy for patients with advanced\/recurrent gastric cancer treated with trastuzumab deruxtecan (T-DXd): EN-hance study. Ann Oncol. 2023;34:S1639\u201340.","journal-title":"Ann Oncol"},{"key":"1670_CR25","doi-asserted-by":"publisher","first-page":"2644","DOI":"10.7150\/jca.87169","volume":"14","author":"H Iihara","year":"2023","unstructured":"Iihara H, Shimokawa M, Bando H, Niwa Y, Mizuno Y, Kawaguchi Y, et al. Doublet or triplet antiemetic prophylaxis for nausea and vomiting induced by trastuzumab deruxtecan: an open-label, randomized, and multicenter exploratory phase 2 study. J Cancer. 2023;14:2644\u201354.","journal-title":"J Cancer"},{"key":"1670_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.09.001","author":"H Sakai","year":"2024","unstructured":"Sakai H, Tsurutani J, Ozaki Y, Ishiguro H, Nozawa K, Yamanaka T, et al. A randomized, double-blind, placebo-controlled phase II study of olanzapine-based prophylactic antiemetic therapy for delayed and persistent nausea and vomiting in patients with HER2-positive or HER2-low breast cancer treated with trastuzumab deruxtecan: ERICA study (WJOG14320B). Ann Oncol. 2024. https:\/\/doi.org\/10.1016\/j.annonc.2024.09.001.","journal-title":"Ann Oncol"},{"key":"1670_CR27","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1056\/NEJMoa1914510","volume":"382","author":"S Modi","year":"2019","unstructured":"Modi S, Saura C, Yamashita T, Park YH, Kim S-B, Tamura K, et al. Trastuzumab deruxtecan in previously treated HER2-positive breast cancer. N Engl J Med. 2019;382:610\u201321.","journal-title":"N Engl J Med"},{"key":"1670_CR28","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1016\/S0140-6736(23)00725-0","volume":"401","author":"F Andr\u00e9","year":"2023","unstructured":"Andr\u00e9 F, Hee Park Y, Kim S-B, Takano T, Im S-A, Borges G, et al. Trastuzumab deruxtecan versus treatment of physician\u2019s choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial. The Lancet. 2023;401:1773\u201385.","journal-title":"The Lancet"},{"key":"1670_CR29","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1056\/NEJMoa2112431","volume":"386","author":"BT Li","year":"2022","unstructured":"Li BT, Smit EF, Goto Y, Nakagawa K, Udagawa H, Mazi\u00e8res J, et al. Trastuzumab deruxtecan in HER2-mutant non-small-cell lung cancer. N Engl J Med. 2022;386:241\u201351.","journal-title":"N Engl J Med"},{"key":"1670_CR30","doi-asserted-by":"publisher","first-page":"4852","DOI":"10.1200\/JCO.23.01361","volume":"41","author":"K Goto","year":"2023","unstructured":"Goto K, Goto Y, Kubo T, Ninomiya K, Kim SW, Planchard D, et al. Trastuzumab deruxtecan in patients with HER2-mutant metastatic non-small-cell lung cancer: primary results from the randomized, phase II DESTINY-Lung02 trial. J Clin Oncol. 2023;41:4852\u201363.","journal-title":"J Clin Oncol"},{"key":"1670_CR31","doi-asserted-by":"publisher","first-page":"2419","DOI":"10.1056\/NEJMoa2004413","volume":"382","author":"K Shitara","year":"2020","unstructured":"Shitara K, Bang YJ, Iwasa S, Sugimoto N, Ryu MH, Sakai D, et al. Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer. N Engl J Med. 2020;382:2419\u201330.","journal-title":"N Engl J Med"},{"key":"1670_CR32","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1016\/S1470-2045(23)00215-2","volume":"24","author":"E Van Cutsem","year":"2023","unstructured":"Van Cutsem E, di Bartolomeo M, Smyth E, Chau I, Park H, Siena S, et al. Trastuzumab deruxtecan in patients in the USA and Europe with HER2-positive advanced gastric or gastroesophageal junction cancer with disease progression on or after a trastuzumab-containing regimen (DESTINY-Gastric02): primary and updated analyses from a single-arm, phase 2 study. Lancet Oncol. 2023;24:744\u201356.","journal-title":"Lancet Oncol"},{"key":"1670_CR33","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1200\/JCO.23.02005","volume":"42","author":"F Meric-Bernstam","year":"2024","unstructured":"Meric-Bernstam F, Makker V, Oaknin A, Oh D-Y, Banerjee S, Gonz\u00e1lez-Mart\u00edn A, et al. Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: primary results from the DESTINY-PanTumor02 phase II trial. J Clin Oncol. 2024;42:47\u201358.","journal-title":"J Clin Oncol"},{"key":"1670_CR34","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1021\/acs.bioconjchem.5b00223","volume":"26","author":"TM Cardillo","year":"2015","unstructured":"Cardillo TM, Govindan SV, Sharkey RM, Trisal P, Arrojo R, Liu D, et al. Sacituzumab govitecan (IMMU-132), an anti-trop-2\/SN-38 antibody-drug conjugate: characterization and efficacy in pancreatic, gastric, and other cancers. Bioconjug Chem. 2015;26:919\u201331.","journal-title":"Bioconjug Chem"},{"key":"1670_CR35","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1158\/1535-7163.MCT-22-0375","volume":"22","author":"A Kopp","year":"2023","unstructured":"Kopp A, Hofsess S, Cardillo TM, Govindan SV, Donnell J, Thurber GM. Antibody-drug conjugate sacituzumab govitecan drives efficient tissue penetration and rapid intracellular drug release. Mol Cancer Ther. 2023;22:102\u201311.","journal-title":"Mol Cancer Ther"},{"key":"1670_CR36","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1016\/S0140-6736(23)01245-X","volume":"402","author":"HS Rugo","year":"2023","unstructured":"Rugo HS, Bardia A, Marm\u00e9 F, Cort\u00e9s J, Schmid P, Loirat D, et al. Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial. The Lancet. 2023;402:1423\u201333.","journal-title":"The Lancet"},{"key":"1670_CR37","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1038\/s41523-022-00467-1","volume":"8","author":"HS Rugo","year":"2022","unstructured":"Rugo HS, Tolaney SM, Loirat D, Punie K, Bardia A, Hurvitz SA, et al. Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer. NPJ Breast Cancer. 2022;8:98.","journal-title":"NPJ Breast Cancer"},{"key":"1670_CR38","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.26127","volume":"6","author":"Q Yang","year":"2023","unstructured":"Yang Q, Zou X, Xie YL, Lin C, Ouyang YF, Liu YL, et al. Fosaprepitant weekly vs every 3 weeks for the prevention of concurrent chemoradiotherapy-induced nausea and vomiting: a pilot randomized clinical trial. JAMA Netw Open. 2023;6: e2326127.","journal-title":"JAMA Netw Open"},{"key":"1670_CR39","doi-asserted-by":"publisher","first-page":"2474","DOI":"10.1200\/JCO.20.03489","volume":"39","author":"ST Tagawa","year":"2021","unstructured":"Tagawa ST, Balar AV, Petrylak DP, Kalebasty AR, Loriot Y, Fl\u00e9chon A, et al. TROPHY-U-01: a phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors. J Clin Oncol. 2021;39:2474\u201385.","journal-title":"J Clin Oncol"},{"key":"1670_CR40","doi-asserted-by":"publisher","first-page":"2329","DOI":"10.1158\/1535-7163.MCT-21-0206","volume":"20","author":"D Okajima","year":"2021","unstructured":"Okajima D, Yasuda S, Maejima T, Karibe T, Sakurai K, Aida T, et al. Datopotamab deruxtecan, a novel TROP2-directed antibody-drug conjugate, demonstrates potent antitumor activity by efficient drug delivery to tumor cells. Mol Cancer Ther. 2021;20:2329\u201340.","journal-title":"Mol Cancer Ther"},{"key":"1670_CR41","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.24.00920","author":"A Bardia","year":"2025","unstructured":"Bardia A, Jhaveri K, Im S-A, Pernas S, Laurentiis MD, Wang S, et al. Datopotamab deruxtecan versus chemotherapy in previously treated inoperable\/metastatic hormone receptor-positive human epidermal growth factor receptor 2\u2013negative breast cancer: primary results from TROPION-Breast01. J Clin Oncol. 2025. https:\/\/doi.org\/10.1200\/JCO.24.00920.","journal-title":"J Clin Oncol"},{"key":"1670_CR42","doi-asserted-by":"publisher","first-page":"2281","DOI":"10.1200\/JCO.23.01909","volume":"42","author":"A Bardia","year":"2024","unstructured":"Bardia A, Krop IE, Kogawa T, Juric D, Tolcher AW, Hamilton EP, et al. Datopotamab deruxtecan in advanced or metastatic HR+\/HER2- and triple-negative breast cancer: results from the phase I TROPION-PanTumor01 study. J Clin Oncol. 2024;42:2281\u201394.","journal-title":"J Clin Oncol"},{"key":"1670_CR43","doi-asserted-by":"publisher","first-page":"4678","DOI":"10.1200\/JCO.23.00059","volume":"41","author":"T Shimizu","year":"2023","unstructured":"Shimizu T, Sands J, Yoh K, Spira A, Garon EB, Kitazono S, et al. First-in-human, phase I dose-escalation and dose-expansion study of trophoblast cell-surface antigen 2\u2013directed antibody-drug conjugate datopotamab deruxtecan in non\u2013small-cell lung cancer: TROPION-PanTumor01. J Clin Oncol. 2023;41:4678\u201387.","journal-title":"J Clin Oncol"},{"key":"1670_CR44","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1016\/j.cmet.2020.10.023","volume":"32","author":"DM Breen","year":"2020","unstructured":"Breen DM, Kim H, Bennett D, Calle RA, Collins S, Esquejo RM, et al. GDF-15 neutralization alleviates platinum-based chemotherapy-induced emesis, anorexia, and weight loss in mice and nonhuman primates. Cell Metab. 2020;32:938-50.e6.","journal-title":"Cell Metab"},{"key":"1670_CR45","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1002\/cam4.3693","volume":"10","author":"HS Park","year":"2021","unstructured":"Park HS, Won HS, An HJ, Cho SS, Kim HH, Sun S, et al. Elevated serum substance P level as a predictive marker for moderately emetogenic chemotherapy-induced nausea and vomiting: a prospective cohort study. Cancer Med. 2021;10:1057\u201365.","journal-title":"Cancer Med"},{"key":"1670_CR46","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1200\/JCO.2024.42.16_suppl.1504","volume":"42","author":"Y Kikawa","year":"2024","unstructured":"Kikawa Y, Uemura Y, Taira T, Kitagawa C, Maeda H, Kato H, et al. A randomized study comparing electronic patient-reported outcome (ePRO) monitoring with routine follow-up during trastuzumab deruxtecan treatment in patients with metastatic breast cancer (PRO-DUCE study). J Clin Oncol. 2024;42:1504.","journal-title":"J Clin Oncol"}],"container-title":["Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12282-025-01670-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12282-025-01670-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12282-025-01670-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T08:05:00Z","timestamp":1740038700000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12282-025-01670-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,29]]},"references-count":46,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["1670"],"URL":"https:\/\/doi.org\/10.1007\/s12282-025-01670-1","relation":{},"ISSN":["1340-6868","1880-4233"],"issn-type":[{"value":"1340-6868","type":"print"},{"value":"1880-4233","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,29]]},"assertion":[{"value":"11 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"HS has received support for the present manuscript (to institution) and medical writing support from Daiichi Sankyo, lecture fees for Daiichi Sankyo, Chugai Pharmaceutical, and Eli Lilly, advisory role fee from Gilead Sciences. JT has received support for the present manuscript from Daiichi Sankyo (to institution), research grants from Eli Lilly, Daiichi Sankyo, and AstraZeneca (to institution), personal fees for Consulting\/honoraria for lectures, presentations, speakers\u2019 bureaus, manuscript writing or educational events\/advisory board from Daiichi Sankyo and AstraZeneca.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}